OSLO (Reuters) – Norwegian authorities will buy the rare-disease treatment Spinraza for patients from U.S. drugmaker Biogen Inc at a cost of 7 million Norwegian crowns ($880,381.33) per year per patient, public broadcaster NRK reported on Monday.
Spinraza treats the rare, often fatal disease spinal muscular atrophy (SMA). Norwegian authorities will cover the costs for minors only.
($1 = 7.9511 Norwegian crowns)
Reporting by Gwladys Fouche, editing by Terje Solsvik